H1 2023 financials included the following statement in relation to royalties etc and was not apparent in todays detail as far is I could ascertain.It is simplistic but clear:
Potential milestone payments and royalties payable to Neuren for NNZ-2591 in Rett and Fragile X are identical to trofinetide milestone payments and royalties in each of the North American and other regions.Neuren retains the worldwide rights to NNZ-2591 in all other indications.
Kens
H1 2023 financials included the following statement in relation...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |